Figure 1. Disease course of the patient. The figure shows the relationship between treatment with thalidomide and octreotide, number of transfusions and hemoglobin. Spiral endoscopy was performed at day 25. Angiodysplasias were treated with argon beaming. Hemoglobin: mmol/L; LAR: Sandostatin® LAR (octreotide). At day 500, the patient was discharged from the outpatient clinic of the Department of Hepato-Gastroenterology with a hemoglobin of 9.3 mmol/L.